CM
GBT

Castleark Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Castleark Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-44,835
Closed -$2.83M – 383
2020
Q2 		$2.83M Sell
44,835
-38,270
-46% -$2.62M 0.12% 159
2020
Q1 		$4.25M Buy
83,105
+55,725
+204% +$3.73M 0.25% 115
2019
Q4 		$2.18M Buy
+27,380
New +$1.62M 0.09% 212
2019
Q2 		– Sell
-89,545
Closed -$4.74M – 412
2019
Q1 		$4.74M Sell
89,545
-1,470
-2% -$72.2K 0.18% 160
2018
Q4 		$3.74M Buy
+91,015
New +$3.41M 0.16% 171

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Castleark Management's GBT Position: Q3 2020 in Review

Castleark Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2020, closing a stake of 44,835 shares — an estimated $2.83M sold.

Castleark Management first reported a position in GBT in Q4 2018 and held it in 5 quarters. The position peaked at $4.74M in Q1 2019. 229 funds tracked by Wall St. Rank hold GBT as of Q3 2020.

  • Castleark Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Castleark Management sold 44,835 Global Blood Therapeutics, Inc. shares in Q3 2020, an estimated $2.83M.
  • Castleark Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2018 and held it in 5 quarters.
  • Castleark Management's Global Blood Therapeutics, Inc. position peaked at $4.74M in Q1 2019.
  • 229 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2020.

Based on Castleark Management's 13F filing for Q3 2020, filed 16 Nov 2020.